(Q40307403)

19 September 2017

title

VEGF-C promotes survival in podocytes (English)

1 reference

19 September 2017

8

P W Mathieson

1 reference

19 September 2017

7

M A Saleem

1 reference

19 September 2017

R R Foster

1

1 reference

19 September 2017

S C Satchell

2

1 reference

19 September 2017

J Seckley

3

1 reference

19 September 2017

M S Emmett

4

1 reference

19 September 2017

K Joory

5

1 reference

19 September 2017

C Y Xing

6

1 reference

19 September 2017

D O Bates

9

1 reference

19 September 2017

S J Harper

10

1 reference

19 September 2017

publication date

8 March 2006

1 reference

American Journal of Physiology - Renal Physiology

19 September 2017

published in

1 reference

19 September 2017

volume

291

1 reference

19 September 2017

issue

1

1 reference

19 September 2017

page(s)

F196-207

1 reference

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Vascular endothelial growth factor C induces angiogenesis in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Restricted expression pattern of vegf-d in the adult and fetal mouse: high expression in the embryonic lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Characterization of murine Flt4 ligand/VEGF-C

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Expression of neuropilin-1 by human glomerular epithelial cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

VEGFR3 gene structure, regulatory region, and sequence polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Hyperplasia of lymphatic vessels in VEGF-C transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Proteolytic processing regulates receptor specificity and activity of VEGF-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Vascular growth factors and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

A model for gene therapy of human hereditary lymphedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

ERK-dependent signaling pathway and transcriptional factor Ets-1 regulate matrix metalloproteinase-9 production in transforming growth factor-beta1 stimulated glomerular podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Angiotensin II increases the intracellular calcium activity in podocytes of the intact glomerulus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Co-localization of nephrin, podocin, and the actin cytoskeleton: evidence for a role in podocyte foot process formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00431.2005

10.1152/AJPRENAL.00431.2005

21 January 2018

Identifiers

DOI

1 reference

release_lm5meg335zaxfkdkxlxci5udti

19 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lm5meg335zaxfkdkxlxci5udti

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference